Address correspondence to Dr Mamatha Pasnoor, 3599 Rainbow Blvd, Mail Stop 2012, Kansas City, KS 66160; email@example.com.
RELATIONSHIP DISCLOSURE: Dr Pasnoor has served on the advisory board of CSL Behring; as a consultant for Momenta Pharmaceuticals, Inc; and as a moderator for the University of California Irvine. Dr Pasnoor has received research/grant support from the National Institutes of Health (NIH) (R01 DK064814). Dr Dimachkie has served as a consultant or on the speaker’s bureau of Alnylam Pharmaceuticals, Inc; Audentes Therapeutics, Inc; CSL Behring; Momenta Pharmaceuticals; Nufactor; RMS Medical Products; Sanofi Genzyme; Takeda; and Terumo Medical Company. Dr Dimachkie has received grants from Alexion Pharmaceuticals, Inc; Alnylam Pharmaceuticals, Inc; Amicus Therapeutics, Inc; BioMarin; Bristol-Myers Squibb Company; Catalyst Pharma; CSL Behring; Genentech, Inc; GlaxoSmithKline plc; Grifols, SA; the Muscular Dystrophy Association; The Myositis Association; the National Institutes of Health; Novartis AG; Sanofi Genzyme; Octapharma; Orphazyme; UCB, Inc; the US Food and Drug Administration/Orphan Products Development; and ViroMed Laboratories.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Pasnoor and Dimachkie report no disclosures.